Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aspira Womens Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aspira Womens Health's regulatory disclosures and financial reporting.
Aspira Women’s Health Inc. reported Q3 2025 results. Revenue was $2,305,000, with gross profit of $1,383,000. Operating expenses were $2,962,000, leading to a loss from operations of $1,579,000. A non-cash loss from the change in fair value of warrant liabilities of $4,309,000 drove total other (expense) income, net to $(3,313,000), and the company recorded a net loss of $4,892,000 for the quarter.
For the nine months ended September 30, 2025, revenue was $6,988,000 and net loss was $9,411,000. Cash and cash equivalents were $3,809,000, working capital was $1,626,000, and long-term debt (DECD loan) was $1,100,000. Warrant liabilities increased to $5,280,000, largely tied to March 2025 warrants measured at fair value. Financing during 2025 included $3,484,000 in gross proceeds under the 2024 at-the-market program and $2,949,000 in gross proceeds from a September 2025 private placement.
The company disclosed substantial doubt about its ability to continue as a going concern within one year. Its common stock was delisted from Nasdaq in April 2025 and began trading on the OTC QX Best Market on October 14, 2025.
Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing lists the company’s common stock trading on the OTC QX Market under the symbol AWHL.
Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.
The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.
Aspira Women’s Health filed Amendment No. 1 to a Form S-1 to register the resale of up to 29,226,527 shares of common stock by selling stockholders. The registered shares comprise: 5,915,850 issued on conversion of senior secured convertible notes, 11,848,177 issuable upon exercise of Amended and Restated March 2025 Warrants, 6,550,000 issued under the September 2025 Purchase Agreement, and 4,912,500 issuable upon exercise of September 2025 Warrants.
The company is not selling any securities in this prospectus and will not receive proceeds from stockholder resales. If the Amended and Restated March 2025 Warrants or September 2025 Warrants are exercised for cash, Aspira estimates it would receive $7,831,237. Sales may occur from time to time using methods described under “Plan of Distribution.” Aspira’s common stock trades on the OTCQB as AWHL; the closing price was $0.52 on September 29, 2025. Shares outstanding were 42,655,918 as of September 29, 2025.
Aspira Women’s Health Inc. reported that on October 14, 2025 it upgraded its trading venue to OTCQX from the OTCQB Venture Market. The company now trades on OTCQX under the symbol AWHL.
Aspira Womens Health Inc. (AWHL) filed a registration statement to register up to 29,226,527 resale shares of its common stock held by selling stockholders. The resale pool comprises shares issued on conversion of convertible notes, shares underlying amended March 2025 warrants, shares issued under a September 2025 purchase agreement, and shares underlying September 2025 warrants. After giving effect to the offering the company expects 59,416,595 shares outstanding based on 42,655,918 shares outstanding as of September 29, 2025. The company will not receive proceeds from the resale by selling stockholders; however, it would receive the nominal cash exercise price if the listed warrants are exercised, estimated at $7,831,237. The prospectus highlights numerous risk factors including limited daily trading volume and concerns about the companys ability to continue as a going concern.
Aspira Women's Health Inc. insider purchase and holdings update. Director Jack W. Schuler, as sole trustee of the Jack W. Schuler Living Trust, reported purchases and existing holdings in AWHL securities. On 09/17/2025 he purchased 1,111,111 shares of common stock at $0.45 per share and now beneficially owns 3,823,829 shares indirectly through the Living Trust. The filing also reports warrants totaling 2,661,422 underlying common shares across multiple strike prices and expirations, including an acquisition of 833,333 warrants exercisable at $0.75 (expiring 09/17/2030). A small disposition of 6,536 common shares and a prior disposal of 6,536 warrants at $2.25 are noted. The report is signed by Jack W. Schuler on 09/18/2025.
Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
FAQ
What is the current stock price of Aspira Womens Health (AWHL)?
What is the market cap of Aspira Womens Health (AWHL)?
